Quick Answer
Innate Pharma SA reported R&D Expense of $51.98 million for fiscal year 2024.
Innate Pharma SA R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $51.98M | -7.2% |
| 2023 | $56.02M | +8.4% |
| 2022 | $51.66M | +9.9% |
| 2021 | $47.00M | -5.4% |
| 2020 | $49.71M | -21.0% |
| 2019 | $62.90M | -9.6% |
| 2018 | $69.56M | +3.8% |
| 2017 | $67.00M | — |
- Innate Pharma SA showed a decrease of -7.2% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2024 period, Innate Pharma SA’s r&d expense has declined by 22.4% (from $67.00 million to $51.98 million).
- The most recent figure is from Innate Pharma SA’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: